Mark G. Lebwohl

Q: What Schools Are Affiliated With Mark G. Lebwohl

Mark G. Lebwohl is affiliated with the following schools: Icahn School of Medicine at Mount Sinai, University of Bordeaux, Columbia University, University of Manchester, Thomas Jefferson University, University of Alabama at Birmingham

Mark G. Lebwohl's AcademicInfluence.com Rankings

Mark G. Lebwohl

Medical

#186

World Rank

#280

Historical Rank

Dermatology

World Rank

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Mark G. Lebwohl Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.

(See a Problem?)

Mark G. Lebwohl's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Secukinumab in plaque psoriasis--results of two phase 3 trials. (2014) (1575)
Psoriasis (1906) (1397)
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008) (1233)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008) (1056)
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. (2001) (1017)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. (2007) (789)
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (2008) (774)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015) (706)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. (2015) (620)
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. (1999) (602)
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. (2003) (579)
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. (2009) (540)
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. (2009) (504)
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. (2011) (493)
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. (2014) (441)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (2019) (437)
Ingenol mebutate gel for actinic keratosis. (2012) (431)
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. (2008) (429)
Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. (2000) (383)
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. (2016) (371)
Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up (2013) (363)
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. (2003) (361)
Methotrexate in psoriasis: consensus conference. (1998) (355)
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. (2010) (335)
Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells (2000) (332)
Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. (2013) (330)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials (2018) (320)
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. (2009) (315)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). (2015) (297)
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. (2004) (274)
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. (2019) (242)
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? (2000) (234)
Cost of atopic dermatitis and eczema in the United States. (2001) (234)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. (2019) (233)
Treatment of psoriasis. Part 1. Topical therapy and phototherapy. (2001) (230)
Treatments for psoriasis and the risk of malignancy. (2009) (225)
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. (2005) (214)
Efficacy and safety of fezakinumab (an IL‐22 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double‐blind, phase 2a trial (2018) (210)
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. (2000) (203)
Finasteride in the treatment of men with frontal male pattern hair loss. (1999) (202)
Identification of possible reactive oxygen species involved in ultraviolet radiation-induced oxidative DNA damage. (1997) (196)
Isoflavone genistein: photoprotection and clinical implications in dermatology. (2003) (193)
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. (1997) (189)
Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. (2012) (189)
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. (1998) (188)
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. (2018) (188)
Treatment of psoriasis. Part 2. Systemic therapies. (2001) (186)
Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. (2001) (179)
Combination therapy to treat moderate to severe psoriasis. (2004) (177)
Classification of pseudoxanthoma elasticum: report of a consensus conference. (1994) (174)
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. (2008) (171)
National Psoriasis Foundation clinical consensus on disease severity. (2007) (163)
Afamelanotide for Erythropoietic Protoporphyria. (2015) (160)
Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. (2015) (159)
Duration of remission of psoriasis therapies. (1999) (158)
Tacrolimus ointment is effective for facial and intertriginous psoriasis. (2004) (158)
Consensus guidelines for the management of plaque psoriasis. (2012) (156)
Pseudoxanthoma elasticum and mitral-valve prolapse. (1982) (155)
Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas. (1999) (154)
US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey (2015) (153)
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up (2015) (153)
Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis. (1988) (150)
Should biologics for psoriasis be interrupted in the era of COVID-19? (2020) (150)
Relapse, rebound, and psoriasis adverse events: an advisory group report. (2006) (145)
Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. (2010) (145)
A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. (1996) (141)
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. (2014) (136)
Association of patient-reported psoriasis severity with income and employment. (2007) (136)
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. (2000) (136)
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey (2015) (135)
Isoflavone genistein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. (1998) (135)
Consensus workshop on the toxic effects of long-term PUVA therapy. (1998) (134)
Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. (2013) (133)
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. (2007) (133)
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis (2017) (131)
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. (1997) (131)
The effect of weight on the efficacy of biologic therapy in patients with psoriasis. (2008) (130)
Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment (2018) (130)
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. (2010) (129)
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials (2017) (128)
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies (2011) (128)
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. (2015) (128)
Induction of 8‐Oxo‐7,8‐Dihydro‐2'‐Deoxyguanosine by Ultraviolet Radiation in Calf Thymus DNA and HeLa Cells (1997) (127)
A clinician's paradigm in the treatment of psoriasis. (2005) (125)
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry (2017) (125)
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. (2004) (123)
Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. (2001) (123)
Psoriasis treatment: traditional therapy (2005) (123)
COLLAGEN ALTERATIONS IN CHRONICALLY SUN‐DAMAGED HUMAN SKIN (1993) (122)
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. (2017) (121)
Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein. (2002) (121)
Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. (2001) (120)
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. (2008) (120)
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. (2003) (119)
AAD consensus statement on psoriasis therapies. (2003) (119)
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. (2003) (118)
Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. (1998) (114)
Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. (2010) (111)
Baseline IL‐22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab (2018) (111)
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. (2005) (110)
Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis. (2006) (110)
The role of salicylic acid in the treatment of psoriasis (1999) (110)
Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. (1995) (110)
Evaluating the economic burden of psoriasis in the United States. (2015) (109)
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. (2010) (109)
Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. (1993) (108)
Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6 (2005) (108)
Research gaps in psoriasis: opportunities for future studies. (2014) (108)
Importance of complete cutaneous examination for the detection of malignant melanoma. (1986) (107)
Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data (2017) (105)
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. (2014) (103)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double‐blind, etanercept‐ and placebo‐controlled study (CIMPACT) (2018) (103)
Therapy for Head Lice Based on Life Cycle, Resistance, and Safety Considerations (2007) (102)
Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. (2012) (102)
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. (2012) (101)
Reactive perforating collagenosis associated with diabetes mellitus. (1982) (100)
Chemoprevention of Nonmelanoma Skin Cancer with Systemic Retinoids: Practical Dosing and Management of Adverse Effects (2006) (98)
Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. (1991) (98)
Inhibition of ultraviolet B (UVB)-induced c-fos and c-jun expression in vivo by a tyrosine kinase inhibitor genistein. (1998) (97)
Actinic keratosis: epidemiology and progression to squamous cell carcinoma (2003) (96)
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review (2018) (95)
Treatment of Skin Disease: Comprehensive Therapeutic Strategies (2005) (93)
CTLA 4 Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris (1999) (92)
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial (2020) (92)
Prevalence and awareness of actinic keratosis: barriers and opportunities. (2013) (92)
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. (2019) (90)
Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. (2009) (89)
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies (2020) (88)
Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks (2019) (85)
A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis (2017) (85)
Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic (2011) (84)
Clinical meaningfulness of complete skin clearance in psoriasis. (2016) (84)
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. (1998) (84)
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. (2010) (84)
Acitretin in combination with UVB or PUVA. (1999) (84)
The effect of secukinumab on moderate‐to‐severe scalp psoriasis: Results of a 24‐week, randomized, double‐blind, placebo‐controlled phase 3b study (2017) (83)
Compatibility of calcipotriene with other topical medications. (1998) (82)
fJoint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. (2020) (82)
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. (2004) (81)
Interactions between calcipotriene and ultraviolet light. (1997) (81)
An update on generalized pustular psoriasis (2019) (80)
Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. (1987) (80)
The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. (2013) (80)
Pseudoxanthoma elasticum is a recessive disease characterized by compound heterozygosity. (2006) (80)
Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. (2009) (79)
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021) (79)
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. (2004) (78)
Bimekizumab versus Secukinumab in Plaque Psoriasis. (2021) (78)
The Use of the 308‐nm Excimer Laser for the Treatment of Vitiligo (2004) (78)
Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. (2003) (77)
Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. (1987) (77)
Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. (2002) (77)
DNA structural integrity and base composition affect ultraviolet light-induced oxidative DNA damage. (1998) (76)
Pediatric Psoriasis Comorbidity Screening Guidelines (2017) (75)
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update (2018) (74)
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). (2016) (73)
Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. (2000) (73)
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. (1991) (73)
Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. (2016) (71)
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis (2010) (71)
Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial (2010) (71)
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. (2012) (70)
Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. (2001) (70)
Protective Effects of Lycopene Against Ultraviolet B-Induced Photodamage (2003) (70)
Impaired skin barrier function in dermatologic disease and repair with moisturization. (2005) (70)
Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). (1989) (69)
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation (2018) (68)
No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. (2005) (68)
Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. (2002) (68)
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. (2016) (67)
Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. (2016) (67)
A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure (2000) (66)
Multiple hamartoma syndrome. (1987) (66)
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments (2021) (66)
Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN (1999) (64)
Retrospective study of the efficacy of narrowband UVB and acitretin (2003) (64)
Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. (1995) (64)
Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. (2003) (64)
Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. (2003) (64)
Pseudoxanthoma elasticum: An Update (1999) (64)
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies (2015) (63)
Topical corticosteroids in psoriasis: strategies for improving safety (2010) (62)
From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. (2014) (62)
Workshop on pseudoxanthoma elasticum: molecular biology and pathology of the elastic fibers. Jefferson Medical College, Philadelphia, Pennsylvania, June 10, 1992. (1992) (62)
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10 (2017) (61)
Pseudoxanthoma elasticum maps to an 820-kb region of the p13.1 region of chromosome 16. (1999) (61)
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy (2019) (61)
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. (2009) (60)
Combining systemic retinoids with biologic agents for moderate to severe psoriasis (2008) (60)
Recalcitrant pyoderma gangrenosum: treatment with thalidomide. (1998) (60)
Characterization of disease burden, comorbidities, and treatment use in a large, US‐based cohort: Results from the Corrona Psoriasis Registry (2018) (60)
Clinical features of pyoderma gangrenosum and current diagnostic trends. (2011) (59)
A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis (2002) (59)
Interventions for nail psoriasis. (2013) (59)
New biologics for psoriasis and psoriatic arthritis (2009) (59)
Combining the new biologic agents with our current psoriasis armamentarium. (2003) (58)
Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. (2011) (58)
UV-A and UV-B penetration of normal human cadaveric fingernail plate. (2011) (58)
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. (2014) (58)
Ultraviolet radiation in alpine skiing: magnitude of exposure and importance of regular protection. (2003) (58)
Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome. (2003) (58)
Topical application of calcipotriene and corticosteroids: combination regimens. (1997) (58)
Phototherapy in dermatology: A call for action. (2015) (58)
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. (1996) (57)
Differential regulation of P53 and Bcl-2 expression by ultraviolet A and B. (1998) (56)
The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. (1998) (56)
Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. (2015) (56)
Benzo[a]pyrene enhances the formation of 8-hydroxy-2'-deoxyguanosine by ultraviolet A radiation in calf thymus DNA and human epidermoid carcinoma cells. (1998) (56)
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. (1998) (55)
Review of safety and efficacy of approved systemic psoriasis therapies (2018) (55)
Herpes zoster in psoriasis patients treated with tofacitinib (2017) (54)
Infectious complications of erythrodermic psoriasis. (1996) (54)
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register (2010) (54)
Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. (2006) (52)
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. (2006) (52)
Treatment of vitiligo using the 308-nm excimer laser. (2006) (52)
Cutaneous ulceration caused by methotrexate. (2003) (52)
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) (2018) (51)
Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage. (2002) (50)
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3 (2018) (50)
The Psoriasis Symptom Diary: development and content validity of a novel patient‐reported outcome instrument (2014) (50)
The Combination of Benzo[a]pyrene and Ultraviolet A Causes an In Vivo Time-related Accumulation of DNA Damage in Mouse Skin¶ (2003) (49)
“COVID arm”: A reaction to the Moderna vaccine (2021) (49)
Subcutaneous fat necrosis of the newborn with hypercalcemia. (1987) (49)
Patient education and regular surveillance results in earlier diagnosis of second primary melanoma (2007) (49)
Metastatic Crohn's disease. (1984) (49)
Atopic dermatitis (1998) (48)
Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies. (2020) (48)
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. (2006) (48)
Trial of Spesolimab for Generalized Pustular Psoriasis. (2021) (48)
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. (2004) (48)
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. (2017) (47)
The use of systemic immune moderators in dermatology: an update. (2005) (47)
PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2'-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. (1999) (46)
Benzo[a]pyrene and its metabolites combined with ultraviolet A synergistically induce 8-hydroxy-2'-deoxyguanosine via reactive oxygen species. (2005) (46)
Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. (2001) (46)
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. (2020) (45)
An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. (2005) (45)
Combination therapy with vitamin D analogues (2001) (45)
Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor. (2018) (45)
International Centennial Meeting on Pseudoxanthoma Elasticum: progress in PXE research. (1998) (44)
A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. (2010) (44)
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 (2020) (43)
Rapid onset of action in patients with moderate‐to‐severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE‐2 and AMAGINE‐3) (2017) (43)
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. (2013) (43)
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3) (2017) (43)
Oral phosphate binders in the treatment of pseudoxanthoma elasticum. (2005) (43)
Topical calcitriol is degraded by ultraviolet light. (2003) (43)
Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments (2001) (43)
Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticum (2005) (41)
Nonstandard and off-label therapies for psoriasis. (2008) (41)
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. (2000) (41)
Trial of Roflumilast Cream for Chronic Plaque Psoriasis. (2020) (41)
Biologics and Psoriasis: The Beat Goes On. (2019) (41)
Long-Term Efficacy and Safety of Tretinoin Emollient Cream 0.05% in the Treatment of Photodamaged Facial Skin (2005) (40)
Interactions between tazarotene and ultraviolet light. (1999) (40)
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. (2007) (40)
Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks--apparent regression with hemodialysis. (1998) (40)
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate‐to‐severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials (2018) (40)
Tacrolimus ointment in the treatment of eyelid dermatitis. (2004) (40)
Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. (1994) (39)
Itch: an under‐recognized problem in psoriasis (2019) (39)
Topical calcipotriene in combination with UVB phototherapy for psoriasis (1997) (39)
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. (2002) (38)
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure (2019) (38)
Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. (1997) (38)
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. (2018) (38)
Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo. (1998) (38)
Pseudoxanthoma elasticum and calcinosis cutis. (2000) (37)
Elastin Gene Deletions in Williams Syndrome Patients Result in Altered Deposition of Elastic Fibers in Skin and a Subclinical Dermal Phenotype (2000) (37)
p53 Mutations in Basal Cell Carcinomas Arising in Routine Users of Sunscreens (1999) (36)
Topical therapy for psoriasis. (1995) (36)
Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry (2019) (36)
Biologics in combination with nonbiologics: efficacy and safety (2004) (36)
Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. (2011) (35)
Elastase-like protease and elastolytic activities expressed in cultured dermal fibroblasts derived from lesional skin of patients with pseudoxanthoma elasticum, actinic elastosis, and cutis laxa. (1988) (35)
Acitretin suppression of squamous cell carcinoma: Case report and literature review (2003) (35)
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis (2015) (35)
Synergistic enhancement of H2O2 production in human epidermoid carcinoma cells by Benzo[a]pyrene and ultraviolet A radiation. (2003) (35)
Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). (2020) (35)
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials (2020) (35)
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare (2021) (35)
Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. (1999) (35)
Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials (2016) (35)
Ultraviolet radiation increases tropoelastin accumulation by a post-transcriptional mechanism in dermal fibroblasts. (1995) (34)
Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells. (1986) (34)
Basement membrane proteins, interstitial collagens, and fibronectin in neurofibroma. (1985) (34)
Psoriasis and the metabolic syndrome (2010) (34)
Serlopitant for Psoriatic Pruritus: a Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial. (2020) (33)
Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I (2005) (33)
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. (2010) (33)
Proven efficacy of tacrolimus for facial and intertriginous psoriasis. (2005) (33)
Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. (2017) (32)
Cutaneous mycobacteriosis: occurrence and significance in two patients with the acquired immunodeficiency syndrome. (1987) (32)
Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies. (2016) (32)
Methotrexate and psoriasis: consensus conference. (2011) (32)
Combined subcarcinogenic benzo[a]pyrene and UVA synergistically caused high tumor incidence and mutations in H‐ras gene, but not p53, in SKH‐1 hairless mouse skin (2005) (32)
Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity (2017) (32)
Association between acrochordons and colonic polyps. (1986) (31)
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. (2021) (31)
Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. (1998) (31)
Cutaneous manifestations of inflammatory bowel disease. (1998) (31)
Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials (2018) (31)
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata (2018) (31)
Long-term etanercept in pediatric patients with plaque psoriasis (2012) (31)
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata (2018) (30)
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study. (2020) (30)
Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: Results of a double‐blind, vehicle‐controlled trial (2004) (30)
Potential future dermatological indications for tacrolimus ointment. (2003) (30)
Effects of Ultraviolet B Exposure on the Expression of Proliferating Cell Nuclear Antigen in Murine Skin¶ (2004) (30)
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients (2021) (29)
Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. (2008) (29)
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. (2017) (29)
Newly available treatments for psoriatic arthritis and their impact on skin psoriasis (2003) (29)
Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. (2013) (29)
Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. (2017) (29)
Pathways to managing atopic dermatitis: consensus from the experts. (2013) (29)
Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. (2016) (29)
Tazarotene in combination with topical corticosteroids. (1998) (28)
Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis. (2017) (28)
Water content and other aspects of brittle versus normal fingernails. (2007) (28)
Glycosaminoglycans of skin and urine in pseudoxanthoma elasticum: evidence for chondroitin 6-sulfate alteration. (1986) (28)
Item-level psychometric properties for a new patient-reported psoriasis symptom diary. (2013) (28)
Lack of Significant Skeletal Changes after Long-Term, Low-Dose Retinoid Therapy: Case Report and Review of the Literature (2006) (28)
Australasian College of Dermatologists Abstracts Presented at the 52nd Annual Scientific Meeting 18–21 May 2019 Melbourne Convention and Exhibition Centre Melbourne, Victoria (2019) (28)
Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. (2009) (28)
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. (2020) (28)
In vitro compatibility of tazarotene with other topical treatments of psoriasis. (2000) (28)
New developments in the treatment of psoriasis. (2002) (28)
Brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with anti-interleukin-17A therapies. (2019) (28)
A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. (2011) (27)
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial. (2021) (26)
Prominent mental (chin) crease: a new sign of pseudoxanthoma elasticum. (2003) (26)
Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient (1997) (26)
From the literature: intralesional 5-FU in the treatment of hypertrophic scars and keloids: clinical experience. (2000) (26)
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis (2020) (25)
Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. (2014) (25)
A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis. (2011) (25)
A comparison of once‐daily application of mometasone furoate 0.1% cream compared with twice‐daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone (1999) (25)
Patient-reported impact of chronic urticaria compared with psoriasis in theUnited States (2017) (25)
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab (2021) (25)
Retrospective analysis of the treatment of psoriasis of the palms and soles (2003) (25)
Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2019) (25)
Effect of secukinumab on quality of life and psoriasis‐related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52‐week study (2017) (25)
TNF inhibitors for psoriasis (2018) (25)
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY) (2020) (24)
Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. (2019) (24)
Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. (1998) (24)
Treatment of Verrucae Vulgaris with α2 Interferon (1986) (24)
Potential complications associated with the use of biologic agents for psoriasis. (2007) (24)
Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography. (1990) (24)
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry (2019) (24)
Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. (2015) (23)
Cutaneous reactions to vitamin K1 injections. (1993) (23)
A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. (2013) (23)
Cutaneous manifestations of inflammatory bowel disease (2000) (23)
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study (2019) (23)
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists (2021) (22)
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry (2020) (22)
Optimizing topical therapies for treating psoriasis: a consensus conference. (2010) (22)
Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab. (2010) (22)
Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. (1985) (22)
Case studies in severe psoriasis: A clinical strategy (2003) (22)
Calcification of elastic fibers in pseudoxanthoma elasticum. (1996) (22)
Physician perceptions and experience of current treatment in actinic keratosis (2015) (22)
Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis (2001) (21)
Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. (1992) (21)
Disease of the dermis (1990) (21)
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study (2019) (21)
Efficacy and safety of ixekizumab over 4 years of open‐label treatment in a phase 2 study in chronic plaque psoriasis (2018) (21)
Moderate-to-Severe Psoriasis (2008) (21)
Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. (2009) (21)
The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. (2010) (21)
Treatment of mycosis fungoides with oral bexarotene combined with PUVA. (2002) (21)
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial (2011) (21)
Development of the US PSORIQoL: a psoriasis‐specific measure of quality of life (2004) (20)
Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council (2011) (20)
Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2018) (20)
Multiple hamartoma syndrome with osteosarcoma. (1993) (20)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. (2019) (20)
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways (2020) (20)
Secukinumab sustains early patient‐reported outcome benefits through 1 year: Results from 2 phase III randomized placebo‐controlled clinical trials comparing secukinumab with etanercept (2017) (19)
Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate (2005) (19)
Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. (2001) (19)
Interventions for nail psoriasis (Review) (2013) (19)
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (2017) (19)
Tinea versicolor treated with terbinafine 1% solution (1999) (19)
New onset and exacerbation of psoriasis after COVID-19 vaccination (2021) (19)
Long-term management of scalp psoriasis: perspectives from the international psoriasis council (2013) (19)
Pseudoxanthoma elasticum and pregnancy. (1996) (19)
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence (2020) (19)
Mammographic findings in pseudoxanthoma elasticum. (2003) (19)
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials (2018) (18)
Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. (1996) (18)
Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. (1996) (18)
Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial. (2020) (18)
LIMITED APPLICATION OF MOMETASONE FUROATE ON THE FACE AND INTERTRIGINOUS AREAS: ANALYSIS OF SAFETY AND EFFICACY (1993) (18)
Psoriasis: Overview and Diagnosis (2018) (18)
The cost of psoriasis treatment (2001) (18)
Retrospective analysis of the treatment of psoriasis of the palms and soles. (2004) (18)
Treatment of psoriasis with crisaborole (2018) (18)
Eosinophilic fasciitis associated with tryptophan ingestion. A manifestation of eosinophilia-myalgia syndrome. (1991) (18)
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam (2019) (18)
Immunogenicity and Skin Clearance Recapture in Clinical Studies of Brodalumab. (2020) (17)
Advances in psoriasis therapy. (2000) (17)
Clinical management of psoriasis: principles and practice. (2001) (17)
Dermatologic findings in 2 patients with COVID-19 (2020) (17)
Long‐term safety results from a phase 3 open‐label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis (2019) (17)
Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile (2017) (16)
Daily UVB exposure levels in high-school students measured with digital dosimeters. (2003) (16)
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. (2006) (16)
Abnormalities of fibrillin in acquired cutis laxa. (1994) (16)
The state and consequences of dermatology drug prices in the United States. (2016) (16)
Use of Ber‐EP4 protein in recurrent metastatic basal cell carcinoma: a case report and review of the literature (2004) (16)
Abnormalities of fibrillin in acquired cutis laxa. (1994) (16)
An open‐label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas (2002) (15)
Presence of type I and VI collagen mRNAs in endothelial cells in cutaneous neurofibromas. (1991) (15)
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups (2019) (15)
Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis. (2018) (15)
In the clinic. Psoriasis. (2011) (15)
Cutaneous manifestations of cardiovascular diseases. (2008) (15)
Use and abuse of topical corticosteroids in infections of the skin and related structures. (2003) (14)
Efficacy and safety of ustekinumab in adolescents (2016) (14)
The penetration of 0.005% fluticasone propionate ointment in eyelid skin. (2001) (14)
Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities? (2017) (14)
Amyloidosis cutis dyschromica associated with atypical Parkinsonism, spasticity and motor weakness in a Pakistani female (2011) (14)
Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up (2021) (14)
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data (2022) (14)
Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations (2017) (14)
Review of therapy of psoriasis: the prebiologic armamentarium. (2004) (13)
Reactive angioendotheliomatosis and sarcoidosis (2002) (13)
Acquired ichthyosis and hyperparathyroidism. (1989) (13)
Adherence to topical therapies in actinic keratosis: A literature review (2016) (13)
Imiquimod cream in the treatment of actinic keratoses. (2002) (13)
Pseudoxanthoma elasticum: Temporary treatment of chin folds and lines with injectable collagen. (2003) (13)
Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial (2020) (13)
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis (2016) (13)
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy (2018) (13)
Acne therapy: clinical pearls. (2001) (13)
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. (2022) (13)
Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials (2020) (13)
Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials (2017) (13)
Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study (2011) (12)
Genital Lentigines in a 6-Year-Old Boy with a Family History of Cowden's Disease: Clinical and Genetic Evidence of the Linkage Between Bannayan-Riley-Ruvacalba Syndrome and Cowden's Disease (2001) (12)
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis (2020) (12)
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial (2021) (12)
Two-Year US Pharmacovigilance Report on Brodalumab (2020) (12)
Efalizumab in the treatment of psoriasis (2004) (12)
Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials (2020) (12)
Should we switch from combination UVA/UVB phototherapy units to narrowband UVB? (2002) (12)
An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. (2014) (12)
Use of Etanercept in the Dermatology Setting (2005) (12)
Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial. (2019) (12)
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy (2011) (12)
Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2). (2020) (11)
6-Thioguanine in the Treatment of Psoriasis: A Case Report and Literature Review (2002) (11)
Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis (2021) (11)
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. (2005) (11)
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. (2013) (11)
Different dosing regimens of imiquimod 5% cream can be used to safely and effectively treat actinic keratosis1 (2004) (11)
A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis (2018) (11)
313 A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb (2017) (11)
Ingenol mebutate (ingenol 3-angelate, PEP005): focus on its uses in the treatment of nonmelanoma skin cancer (2012) (11)
Vitamin D and topical therapy. (2002) (11)
Innovations in the treatment of psoriasis. (2004) (11)
Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials (2020) (11)
What's New in Psoriasis. (2019) (11)
Dermatological signs of internal disease. 2nd ed. (1996) (11)
The use of the 308-nm excimer laser for the treatment of psoriasis. (2010) (11)
Continuance on etanercept after early incomplete response in patients with psoriasis (2004) (11)
Psoriasis and stress (1998) (11)
Risk of Skin Disorders in Patients with Celiac Disease: A Population-Based Cohort Study. (2020) (11)
Alopecia areata profiling shows T H 1, T H 2, and IL-23 cytokine activation without parallel T H 17/T H 22 skewing (2015) (11)
The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. (2007) (10)
Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis (2021) (10)
New roles for systemic retinoids. (2006) (10)
Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema (2016) (10)
Three‐year U.S. pharmacovigilance report of brodalumab (2021) (10)
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. (2022) (10)
Clinical Pearl: Vitamin E (α-tocopherol), 800 IU daily, may reduce retinoid toxicity (1999) (10)
Topical Calcineurin Inhibitors (2006) (10)
Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies (2020) (10)
The use of alefacept in the treatment of psoriasis. (2003) (10)
Global safety and efficacy of more than 5 years of etanercept therapy in rheumatoid arthritis (2004) (10)
Mild to Moderate Psoriasis (2006) (10)
One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial. (2022) (10)
Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial (2011) (9)
Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment. (2018) (9)
Diseases of the dermis. (1990) (9)
Efficacy of Ruxolitinib Cream in Vitiligo by Patient Characteristics and Affected Body Areas: Descriptive Subgroup Analyses From a Phase 2, Randomized, Double-Blind Trial. (2021) (9)
Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. (1997) (9)
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). (2020) (9)
Hat-wearing patterns in persons attending baseball games. (2006) (9)
Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment (2019) (9)
Complications of the smallpox vaccine (2005) (9)
EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS (2018) (9)
A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA). (2005) (9)
Frequency of Culture‐Proven Dermatophyte Infection in Patients with Suspected Tinea Pedis (2004) (9)
A preliminary 18F-FDG-PET/MRI study shows increased vascular inflammation in moderate-to-severe atopic dermatitis. (2020) (8)
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry (2020) (8)
Psoriasis and Crohn's disease. (1999) (8)
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis (2003) (8)
New treatments for alopecia areata (1997) (8)
Clinical efficacy and safety of tazarotene: optimizing clinical results. (1998) (8)
Time Trends in Epidemiology and Characteristics of Psoriatic Arthritis Over 3 Decades: A Population-based Study (2010) (8)
Elastase digestion of normal and pseudoxanthoma elasticum lesional skin elastins. (1991) (8)
Future psoriasis therapy. (1995) (8)
Erratum: Pseudoxanthoma elasticum maps to an 820-kb region of the p13.1 region of chromosome 16 (Genomics (1999) 62: 1 (1)) (2000) (8)
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up (2021) (8)
Chronic lichen sclerosus successfully treated with intralesional adalimumab (2016) (8)
Melkersson-Rosenthal syndrome successfully treated with adalimumab. (2018) (8)
Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatology. (2004) (8)
Ustekinumab as therapy for psoriasis in a 2‐year‐old girl (2016) (8)
Treatment of Severely Recalcitrant Chronic Spontaneous Urticaria: A Discussion of Relevant Issues (2015) (8)
Alefacept: where it stands today (2010) (8)
Pyoderma Gangrenosum versus Chronic Venous Ulceration: Comparison of Diagnostic Features (2006) (8)
Granuloma annulare skin profile shows activation of Th1, Th2, and JAK pathways. (2019) (8)
The evolution of vitamin D analogues for the treatment of psoriasis. (1995) (8)
Sterility of refrigerated injectable collagen syringes after injection of patient. (1992) (8)
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD (2020) (8)
What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab. (2018) (8)
Combination, Rotational, and Sequential Therapies (2008) (8)
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data. (2021) (7)
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2). (2020) (7)
The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists. (2018) (7)
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis (2022) (7)
Atlas of the Skin and Systemic Disease (1995) (7)
Inferferon and Condylomata Acuminata (1990) (7)
Continued treatment with secukinumab is associated with high retention or regain of response (2019) (7)
No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. (2020) (7)
Translating psoriasis guidelines into practice: Important gaps revealed. (2016) (7)
Treatment of verrucae vulgaris with alpha 2 interferon. (1986) (7)
Overview on desonide 0.05%: a clinical safety profile. (2004) (7)
More on PML in Patients Treated with Dimethyl Fumarate. (2016) (7)
Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis (2019) (6)
Dupilumab as a treatment for generalized idiopathic pruritus: a report of two cases (2019) (6)
The case for micrographically controlled skin surgery. (2000) (6)
Hyaluronic acid and dermatan sulfate in non-lesional pseudoxanthoma elasticum skin. (1995) (6)
Etanercept in patients with psoriatic arthritis: sustained improvement in skin and joint disease (2004) (6)
Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials (2021) (6)
One-Year Pharmacovigilance Update of Brodalumab. (2020) (6)
Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. (2002) (6)
Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings (2008) (6)
Biologics for psoriasis: a translational research success story. (2015) (6)
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. (2022) (6)
Improvement in scalp and nails with apremilast in patients with moderate plaque psoriasis naive to systemic and biologic therapy: 52-week results of the UNVEIL study (2018) (6)
Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies (2020) (6)
Once-Weekly Administration of Etanercept 50mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis (2011) (6)
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis (2019) (6)
Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials (2017) (6)
The Psoriasis Decision Tree. (2021) (6)
TherapeuTics for The clinician Calcitriol Ointment 3 μg / g Is Safe and Effective Over 52 Weeks for the Treatment of Mild to Moderate Plaque Psoriasis (2009) (6)
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (2021) (6)
Treatment of COVID‐19 induced chilblains with topical nitroglycerin (2020) (6)
Biologic Therapy and the Risk of Malignancy in Psoriasis (2011) (5)
Interleukin 12/23 agents and major adverse cardiovascular events. (2012) (5)
Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study (2021) (5)
6-Thioguanine in the Treatment of Psoriasis: A Case Report and Literature Review (2002) (5)
Successful Treatment of Palmoplantar Psoriasis Using Combination Acitretin and Apremilast: A Case Report (2016) (5)
Erratum: Proceedings of the psoriasis combination and rotation therapy conference (Journal of the American Academy of Dermatology (1996) 34 (315- 321)) (1996) (5)
Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials (2020) (5)
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis (2018) (5)
Necrolytic migratory erythema associated with a metastatic neuroendocrine tumor. (2011) (5)
Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel (2016) (5)
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis (2022) (5)
Clinical pearl: vitamin E (alpha-tocopherol), 800 IU daily, may reduce retinoid toxicity. (1999) (5)
L-Carnitine Reduces Muscle Cramps in Patients taking Vismodegib (2018) (5)
Impact of etanercept treatment on ultraviolet B-induced inflammation, cell cycle regulation and DNA damage (2012) (5)
Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials (2021) (5)
Newer Therapies in Psoriasis. (2021) (5)
New cutaneous manifestations of systemic diseases. (1995) (5)
The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities. (2020) (5)
Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update (2019) (5)
Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist (2005) (5)
Treatment of Refractory Psoriasis with Ustekinumab in an HIV-Positive Patient: A Case Presentation and Review of the Biologic Literature (2014) (5)
Efficacy and Safety of Crisaborole Topical Ointment, 2%, a Novel, Nonsteroidal, Topical, Anti-Inflammatory, Phosphodiesterase Inhibitor in 2 Phase 3 Studies in Children and Adults with Mild-to-Moderate Atopic Dermatitis (2016) (4)
Review of Available and Investigational Biologics and Non-Biologic Small Molecules for the Treatment of Plaque Psoriasis (2016) (4)
crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: Results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis : 3519 (2016) (4)
Clinics in dermatology: Pseudoxanthoma elasticum (1989) (4)
Secukinumab is Superior to Ustekinumab in Clearing Skin of Patients with Moderate to Severe Plaque Psoriasis: CLARITY, a Randomized, Controlled, Phase 3b Trial (2018) (4)
Biopsy techniques: shave, punch, or excision? (2014) (4)
Acitretin suppression of squamous cell carcinoma1 (2004) (4)
Clinically significant therapeutic interactions for the practicing dermatologist. (1999) (4)
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes (2011) (4)
Adverse Effects of Systemic Treatments: Methotrexate (1997) (4)
Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States (2019) (4)
Immunofluorescence and electron microscopic findings in a congenital arrector pili hamartoma. (1989) (4)
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis (2021) (4)
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2 (2022) (4)
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm (2021) (4)
The Successful Treatment of Multiple Cutaneous Malignancies with HPV Vaccination: Case Report (2020) (4)
Acanthosis nigricans in a plaque of scleredema on the back of a diabetic patient: A case report (2005) (4)
A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses. (2008) (4)
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis (2020) (4)
Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry (2018) (4)
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials (2019) (4)
Do we need more psoriasis therapies? (2015) (4)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis. (2011) (4)
Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials (2018) (4)
Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis (2017) (4)
Combination of Apremilast and Narrowband UVB in the Treatment of Generalized Vitiligo in Skin Types IV-VI: A Randomized Split-Body Pilot Study. (2021) (4)
What the National Psoriasis Foundation means to dermatologists and our patients. (2008) (4)
Compatibility of topical therapies for psoriasis: challenges and innovations. (2007) (4)
Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution” (2020) (4)
PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS (2009) (4)
p53 Gene Mutations in SKH‐1 Mouse Tumors Differentially Induced by UVB and Combined Subcarcinogenic Benzo[a]pyrene and UVA † (2008) (4)
Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs (2019) (4)
Interleukin-23 blockade: another breakthrough in the treatment of psoriasis (2019) (4)
Cutaneous reaction reported after third Moderna COVID-19 vaccine (2021) (4)
Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data (2014) (3)
Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial (2018) (3)
Impact on quality of life and satisfaction with apremilast in patients with moderate plaque psoriasis: 52-week results of the UNVEIL study (2018) (3)
Improving the safety profile of long-term PUVA therapy. (1999) (3)
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study (2022) (3)
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata (2022) (3)
FRI0123 Clinical Outcomes Associated with Switching or Discontinuation of Anti-TNF Inhibitors for Non-Medical Reasons (2015) (3)
SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis (2013) (3)
Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies (2021) (3)
Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial (2021) (3)
Advances in psoriasis. (2005) (3)
Prospective Cohort Study of Psoriatic Arthritis Risk in Patients With Psoriasis in a Real-World Psoriasis Registry. (2022) (3)
Terbinafine (1%) solution and emulsion gel: Two new formulations in one-week treatment of tinea pedis and tinea corporis/cruris (1998) (3)
Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. (2017) (3)
Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data (2022) (3)
Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis. (2012) (3)
Patient Perspectives on Psoriasis Management: U.S. Results of the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey (2014) (3)
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis (2021) (3)
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI (2022) (3)
Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Psoriasis Therapies (2002) (3)
A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris (1998) (3)
Reduced burning and stinging associated with topical application of lactic acid 10% with strontium versus ammonium lactate 12%. (2013) (3)
Treating Scalp Psoriasis with Calcipotriol/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 data. (2020) (3)
Iatrogenic effects of biologics for psoriasis. (2011) (3)
Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology? (2016) (3)
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits (2021) (3)
Do we need a patient satisfaction score? (2014) (3)
Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study (2017) (3)
Treatment of a large high-grade neurofibrosarcoma with concomitant vinblastine, doxorubicin, and radiotherapy. (1992) (3)
Burden of Psoriasis as Reported in a Cross-Sectional Study: Association of Psoriasis Severity with Health-Related Quality of Life, Depression, and Work Productivity (2017) (3)
Recent advances in medical dermatology (2007) (3)
Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors". (2015) (3)
Regression Analysis of Local Skin Reactions to Predict Clearance of Actinic Keratosis on the Face in Patients Treated With Ingenol Mebutate Gel: Experience from Randomized Controlled Trials. (2017) (3)
Indications and limitations of afamelanotide for treating vitiligo-reply. (2015) (3)
Actinic Keratosis. (2016) (3)
Adverse Effects of Systemic Psoriasis Treatments: Retinoids (1997) (3)
Interleukin 17 Inhibitors (2021) (2)
Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis (2018) (2)
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score (2021) (2)
Biosimilars in Dermatology. (2021) (2)
Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis. (2015) (2)
Mycophenolate Mofetil for Psoriasis (1998) (2)
Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control study (2010) (2)
A multi-center study of calcipotriene 0.005% ointment and clobetasol proprionate 0.05% foam in the sequential treatment of localized plaque-type psoriasis1 (2004) (2)
Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study) (2017) (2)
A new standardized method of evaluating cutaneous irritation from topical medications. (2008) (2)
Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) (2019) (2)
Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasis. (2020) (2)
Pitfalls in the Use of Dovonex (1995) (2)
Images in clinical medicine. Pseudoxanthoma elasticum. (1993) (2)
Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept (2016) (2)
34660 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials (2022) (2)
Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study) (2017) (2)
Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion (2020) (2)
Phase I trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB) (1998) (2)
Differential diagnosis of pigmented lesions of the skin. (1992) (2)
16332 Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis (2020) (2)
Free Communications: 81st Annual Meeting of the Swiss Society for Dermatology and Venereology (1999) (2)
Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study. (2022) (2)
PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS (2008) (2)
Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials (2021) (2)
PSS44 USTEKINUMAB IMPROVES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS (2008) (2)
Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial (2020) (2)
New strategies for optimizing the treatment of inflammatory dermatoses with topical corticosteroids in an era of corticosteroid-sparing regimens (2005) (2)
14027 Long-term efficacy and safety of continuous q12w risankizumab: Results from the open-label extension LIMMitless trial (2020) (2)
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics (2021) (2)
Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT) (2017) (2)
Asymmetric Prurigo Nodularis after Paralysis: A Case Report (2020) (2)
Reply to: “Biologics for psoriasis during COVID-19 outbreak” (2020) (2)
Frequency of Monotherapy versus Combination Therapy in Reported Cases of Infections Occurring in the Setting of Biologic Agents (2013) (2)
ixekizumab shows no association with major adverse cardiac events (mace) in patients with moderate-to-severe psoriasis: An integrated safety analysis of clinical trials : 3413 (2016) (2)
CYCLOSPORINE-ASSOCIATED LYMPHOMA. AUTHORS' REPLY (1999) (2)
Apremilast for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case Series (2017) (2)
Therapy for Severe Psoriasis (2016) (2)
Adult-onset asymmetrical lipomatosis. (2019) (2)
Certolizumab pegol is effective for chronic plaque psoriasis regardless of previous exposure to systemic therapy: A pooled subanalysis of ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT) (2018) (2)
Different dosing regimens of imiquimod 5% cream can be used to safely and effectively treat actinic keratosis 1 1 All authors have been paid study investigators and/or consultants for 3M Pharmaceuticals. (2004) (2)
13883 Maintenance of response through 136 weeks of long-term continuous risankizumab treatment: An analysis of patients from UltIMMa-1 and UltIMMa-2 (2020) (2)
Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study (2018) (2)
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression Up to 52 Weeks: An Overview From Secukinumab Phase 3 Clinical Trials (2017) (2)
Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies (2020) (2)
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice (2019) (2)
The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry (2022) (2)
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (2019) (2)
Cost-effectiveness of methotrexate and Goeckerman therapy: a flawed analysis. (1999) (2)
Durable remissions of guttate psoriasis following short courses of IL‐17 inhibitors (2021) (2)
434 Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab (2018) (2)
Adverse Effects of Systemic Treatments: Cyclosporine (1998) (2)
Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema (2012) (2)
27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial (2021) (1)
Appropriate Use of Alefacept Therapy for Psoriasis (2004) (1)
15960 Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2) (2020) (1)
Topical antipsoriatics. (2000) (1)
15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: Results from IBM MarketScan databases (2020) (1)
CONTENTS WHAT'S NEW IN THE MEDICINE CHEST? (2009) (1)
Furuncular Cutaneous Myiasis (1)
PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL (2008) (1)
FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES (2020) (1)
Treating Scalp Psoriasis With Fixed-dose Combination Calcipotriene/Betamethasone Dipropionate Cutaneous Foam: Review of Phase 2 Data (2020) (1)
Original Contribution Benzo(a)pyrene and its metabolites combined with ultraviolet A synergistically induce 8-hydroxy-2V-deoxyguanosine via reactive oxygen species (2005) (1)
Infrared camera evaluation of the cooling effect of triamcinolone acetonide aerosol. (2013) (1)
Tumour necrosis factor‐α blockers in the treatment of psoriasis (2010) (1)
Comment on “PGA×BSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis” (2020) (1)
What is Known About the Association of Antinuclear Antibodies Development During Treatment with TNF Blockers? (2008) (1)
Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics (2019) (1)
Spesolimab use in treatment of pyoderma gangrenosum (2023) (1)
Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study (2021) (1)
Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials (2015) (1)
SAT0472 Utilization of the psoriasis epidemiology screening tool to identify signs and symptoms of early psoriatic arthritis among those with psoriasis: analysis from the corrona psoriasis registry (2017) (1)
Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study. (2020) (1)
P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses (2021) (1)
Large inflamed facial cysts in teenagers (2020) (1)
Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials (2022) (1)
Comprar Mild-to-Moderate Psoriasis, Second Edition | John Y.M. Koo | 9781420088618 | Informa Healthcare (2009) (1)
Common Adverse Drug-Drug Interactions in Dermatology: Oral Therapies (2017) (1)
Reply to 'complementary data for long-term infliximab use in psoriasis'. (2014) (1)
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances (2022) (1)
Addition of Narrow-Band Ultraviolet Light B (UVB) Phototherapy to Ruxolitinib Cream in Patients With Vitiligo. (2022) (1)
Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study (2019) (1)
26750 Cumulative clinical benefits of biologic treatments for psoriasis over 1 year (2021) (1)
303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo (2021) (1)
Henoch-Schönlein purpura. Case report and review of the literature. (1995) (1)
Article Commentary: The Natural Course of Psoriasis: Data from a Rare ‘Experiment of Nature’ in Maoist China (2017) (1)
The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement (2021) (1)
Two phase 3 studies in atopic dermatitis with crisaborole, the novel, nonsteroidal topical phosphodiesterase 4 inhibitor (2016) (1)
Comprar Treatment of Skin Disease. Comprehensive Therapeutic Strategies 5th ed | Mark G. Lebwohl | 9780702069123 | Elsevier Internacional (2017) (1)
A Review of Current Evidence for TNF Inhibitor Switching in Psoriatic Arthritis (2016) (1)
Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies (2017) (1)
Biologic Drugs and Malignancy: A Literature Review Examining the Impact of Concomitant Immunosuppressive Medications (2012) (1)
A Systematic Review of Neurovascular Complications in Patients with Pseudoxanthoma Elasticum (2020) (1)
27874 Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis (2021) (1)
Evaluation of sensory irritation caused by topical medications using a novel technique (2010) (1)
Retrospective study of the efficacy of narrowband UVB and acitretin for the treatment of psoriasis (2004) (1)
Examining disease severity and symptom improvement with patient and physician assessments: Results from a phase IV analysis of apremilast in patients with moderate plaque psoriasis (2018) (1)
Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) (2018) (1)
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. (2022) (1)
Comment on “Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis” (2019) (1)
Systemic Psoriasis Treatment with Alefacept (2003) (1)
Recapture Rate of Brodalumab in Patients With a Lapse in Treatment. (2020) (1)
Advances and Considerations in the Management of Actinic Keratosis: An Expert Consensus Panel Report. (2021) (1)
Reply to: "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials". (2018) (1)
Advances in Psoriasis: A Multisystemic Guide (2021) (1)
Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study (2020) (1)
Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review (2022) (1)
Telogen Effluvium in Patients recovering from COVID-19 (2021) (1)
PSY46 PATTERNS OF CARE IN THE PHARMACOLOGIC TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (2009) (1)
060 Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials (2016) (1)
A Guide to Systemic Psoriasis Treatments: Retinoids (2000) (1)
16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases (2020) (1)
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis (2021) (1)
Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy (2018) (1)
Diflorasone diacetate cream in an optimized vehicle versus fluocinonide cream for the treatment of psoriasis (1995) (1)
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent (2021) (1)
13677 Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial (2020) (1)
Interleukin 12/23 Inhibitors (2021) (1)
279 Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole (2016) (1)
Apremilast as an Off-Label Therapeutic Agent (2021) (1)
Cimetidine therapy for plantar warts. (1995) (1)
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). (2023) (1)
SAT0559 Malignancies in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations (2015) (1)
Impact of Temperature on Injection-Related Pain Caused by Subcutaneous Administration of Ustekinumab: A Three-arm Crossover Open-label Randomized Controlled Trial (2017) (1)
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey. (2023) (1)
Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial (2021) (1)
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17 (2022) (1)
27368 Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trial (2021) (1)
PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS (2008) (1)
A Rare Finding in an Inflammatory Polyp. (2017) (1)
Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies (2020) (1)
Should the Black Box Warning of Brodalumab and Apremilast Deter Prescribing in Psoriasis Patients with Depression? (2021) (1)
A randomized, double-blind, negatively controlled pilot study to determine whether the use of emollients or calcipotriol alters the sensitivity of the skin to ultraviolet radiation during phototherapy with narrowband ultraviolet B (2012) (1)
A Guide to Systemic Psoriasis Treatments: Cyclosporine (2000) (1)
Long-term topical oxymetazoline hydrochloride 1.0% demonstrates sustained and increasing effect in persistent facial erythema of rosacea (2018) (1)
Comprar Moderate-to-Severe Psoriasis, Third Edition | Chai Sue Lee | 9781420088670 | Informa Healthcare (2009) (1)
The Combination of Benzo[a]pyrene and Ultraviolet A Causes an In Vivo Time‐related Accumulation of DNA Damage in Mouse Skin ¶ (2003) (1)
In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?". (2011) (1)
Letter in response to Egeberg A, Bryld LE, Skov L, Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. (2019) (1)
Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study (2018) (1)
Classification of Psoriasis by its Natural History: A New Perspective from Abroad (2003) (1)
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting (2022) (1)
299 Oral difelikefalin improves itch and inflammatory biomarkers in atopic dermatitis subjects with moderate-to-severe pruritus (2022) (1)
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies (2020) (1)
Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. (2017) (1)
PSEUDOXANTHOMA ELASTICUM. AUTHORS' REPLY (1994) (1)
Clobetasol Propionate Foam, 0.05% (2001) (1)
Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data (2017) (1)
Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis (2021) (0)
Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study (2020) (0)
Supplementary Appendix - Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (2020) (0)
15353 Presence of psoriatic arthritis has no impact on the clinical efficacy and safety of secukinumab in patients with psoriasis: Pooled analysis of four phase 3 clinical trials (2020) (0)
17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics (2020) (0)
Letter from the Editors (2015) (0)
15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry (2020) (0)
P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis (2023) (0)
27124 Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis (2021) (0)
33884 Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life (2022) (0)
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity. (2023) (0)
Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis (2011) (0)
Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends (2019) (0)
16534 Real-world disease severity of patients with psoriasis initiating brodalumab: Findings from the Corrona Psoriasis Registry (2020) (0)
25574 The impact of PASI90 duration on patient reported outcomes among patients with psoriasis (2021) (0)
Etanercept: Dosing, Monitoring and Side Effects (2002) (0)
Mild-to-Moderate Psoriasis, Second Edition (2008) (0)
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2. (2021) (0)
33817 Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial (2022) (0)
Comprar Mild-to-Moderate Psoriasis, Second Edition | Mark G. Lebwohl | 9781420088601 | Informa Healthcare (2009) (0)
Fixed-Dose Corticosteroid/Calcipotriene Combination Therapy (2006) (0)
34320 Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasis (2022) (0)
Tacalcitol : A Viewpoint by J. Baral and M. Lebwohl. (1997) (0)
Cutaneous Carcinogenesis Related to Dermatologic Therapy (2011) (0)
Brodalumab in patients who had inadequate response to ustekinumab (2019) (0)
The Blue Journal 25 Years Ago (2004) (0)
Introduction to Mild-to-Moderate Psoriasis (2008) (0)
P152 CHARACTERIZING THE EFFECTIVENESS OF ABROCITINIB IN SUBTHRESHOLD RESPONDERS IN THE MAINTENANCE PHASE OF JADE REGIMEN (2021) (0)
Spesolimab improves patient‐reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study (2022) (0)
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. (2023) (0)
Two Doses of Subcutaneous Ustekinumab Based on Body Weight Provide Similar Efficacy in Heavier and Lighter Weight Patients With Moderate-to-Severe Psoriasis (2010) (0)
Buchbesprechungen (2006) (0)
Malignancy Events in Patients With a History of Cancer in Clinical Studies of Brodalumab (2020) (0)
Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris. (2007) (0)
27383 Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials (2021) (0)
Palm & Sole Psoriasis: Looking at the Range of Treatments (1996) (0)
18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial (2020) (0)
Spesolimab treatment for people with flares of generalized pustular psoriasis: a plain language summary of the Effisayil™ 1 study (2022) (0)
Expanding the therapeutic options for psoriatic conditions (2004) (0)
PSS30 USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS: RESULTS FROM A PHASE III STUDY (2008) (0)
Fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% topical therapy shows promise in the long-term management of psoriasis (2018) (0)
Successful Treatment of Granuloma Annulare with Certolizumab (2020) (0)
Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab (2019) (0)
Topical therapy II: retinoids, immunomodulators, and others (2008) (0)
26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial (2021) (0)
14087 Integrating genomics for the diagnosis and prognosis of melanoma into clinical practice (2020) (0)
Chapter 13 – Dermatologic Management of Psoriasis (2007) (0)
Cutaneous type adult T-cell leukemia/lymphoma is a characteristic subtype and includes erythema/papule and nodule/tumor subgroups (2011) (0)
Interactions of Common Psoriasis Treatments (2001) (0)
A new era in the treatment of atopic dermatitis (2019) (0)
094 Characterisation of the immunogenicity of spesolimab in patients with a generalized pustular psoriasis (GPP) flare (2022) (0)
E088 Safety of guselkumab in patients with psoriatic disease: an integrated analysis of 11 Phase 2 and 3 clinical studies in psoriasis and psoriatic arthritis (2023) (0)
33150 Safety of guselkumab in patients with moderate-to-severe psoriasis: Pooled analyses across clinical studies (2022) (0)
Immune gene expression in primary melanomas to predict lower risk of recurrence and death. (2013) (0)
26842 Long-term proactive management with Cal/BD foam is beneficial for all patients with psoriasis irrespective of baseline characteristics (2021) (0)
Mild to Moderate Psoriasis, Third Edition (2014) (0)
33547 Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scale for assessing severity of GPP (2022) (0)
Tu1306 Clinical Outcomes Associated With Switching or Discontinuation of Anti-TNF Inhibitors for Non-Medical Reasons (2015) (0)
Potentiating effect of Benzo(a)pyrene on ultraviolet radiation-induced 8-hydroxy-2′-deoxyguanosine in purified DNA and human epidermoid carcinoma cells (1998) (0)
294 Extensive alopecia areata is reversed by IL-12/23p40 cytokine antagonism (2016) (0)
Update on Ustekinumab for Psoriasis (2017) (0)
Incorporating Prognostic Gene Expression Profile Assays into the Management of Cutaneous Melanoma: An Expert Consensus Panel (2023) (0)
Letter from the Editors (2018) (0)
31865 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis (2022) (0)
A Practical Approach to the Use of Infliximab (2008) (0)
Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply. (2023) (0)
Management of Erythrodermic Psoriasis (1998) (0)
Extramammary Paget's disease. (1999) (0)
Update on Risankizumab for Psoriasis (2019) (0)
P95: Update of a systematic review on outcomes in vitiligo trials: international implementation of core outcomes set and recommendations on its further development (2022) (0)
Psychiatric Implications of Psoriasis—Reply (2006) (0)
Transition from methotrexate and cyclosporine to other therapies 1 1 Disclosure not available at pre (2004) (0)
FDA Advisory Panel Targets Topical Immunomodulators (2005) (0)
Letter from the Editors (2018) (0)
COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature (2023) (0)
Cyclosporine for Severe Drug Eruption in a Psoriasis Patient (2020) (0)
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2) (2022) (0)
Conference on Food , Nutrition , and Cancer Isoflavone Genistein : Photoprotection and Clinical Implications in Dermatology 1 , 2 (2003) (0)
Efficacy Trends With Continuous Long-Term Use of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis (AD) (2020) (0)
27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials (2021) (0)
Recent Advances in Drug Therapy for Psoriasis (1999) (0)
P96: Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 156‐week data from a phase II study (2022) (0)
JDD: celebrating 10 years of publishing excellence. (2012) (0)
Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative review. (2022) (0)
Letter to the Editor. (2020) (0)
Chapter 11 – Ustekinumab (2016) (0)
Tazarotene in combination with topical corticosteroids. Discussion (1998) (0)
Skin Diseases Associated with Biologic Therapies (2018) (0)
Letter to the Editor (2000) (0)
Childhood Plaque Psoriasis: Case Report of Successful Treatment with Ustekinumab and Review of Systemic Therapies (2012) (0)
Lyme disease. (2017) (0)
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. (2022) (0)
Immunobiologics: Intermittent versus Continuous Use in the Treatment of Moderate to Severe Psoriasis (2014) (0)
26698 Characteristics and disease burden in patients with mild to moderate vs severe plaque psoriasis in real-world settings: Results from the Corrona Psoriasis Registry (2021) (0)
Sweet’s-like vasculitis induced by granulocyte colony-stimulating factor therapy in a patient with bladder carcinoma (2004) (0)
Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab (2020) (0)
PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial (2019) (0)
Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study) (2023) (0)
27203 Psoriasis Area and Severity Index component scores in clinical trials of brodalumab (2021) (0)
Barriers Imposed by Insurance Companies to Biologic Therapy in Patients with Moderate-to-Severe Psoriasis (2012) (0)
Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report. (2006) (0)
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials (2021) (0)
27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor (2021) (0)
Henoch-Sch√∂nlein purpura. Case report and review of the literature (1995) (0)
Reactive perforating collagenosis. (1998) (0)
16127 Efficacy of ingenol mebutate in patients with actinic keratosis on face and scalp: Subgroup analysis of a 12-month observational follow-up study according to age (<65 and ≥65 years) (2020) (0)
Changing the Wound Healing Landscape — Offloading Stress , Aiding Stem Cells (2014) (0)
27376 Speed of clinical response and improvement in psoriasis with bimekizumab: Pooled results from the multicenter, randomized, double-blinded phase 3 BE VIVID, BE READY and BE SURE trials (2021) (0)
Combination use of systemic therapies in recalcitrant psoriasis (2017) (0)
Comprehensive Literature Review of Obstetric Outcomes and Fetal Risk during Pregnancy with Pseudoxanthoma Elasticum (2021) (0)
The efficacy of secukinumab with continued use in the treatment of psoriasis (2020) (0)
Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE (2021) (0)
Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program (2023) (0)
Annual screening for tuberculosis in patients on TNF-alfa antagonists. (2015) (0)
15308 Frequency of gastrointestinal-related serious adverse events among guselkumab-treated patients with moderate to severe psoriasis: A pooled analysis of Voyage 1 and Voyage 2 through 3 years (2020) (0)
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial (2022) (0)
Reply to research letter (2020) (0)
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. (2023) (0)
Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence (2020) (0)
Comparison of urinary 8-hydroxy-2'-deoxyguanosine in patients treated with topical corticosteroids, UV-B, and psoralen UV-A therapies. (2000) (0)
Dear Colleagues (2017) (0)
The Reliability of Disease Severity Assessment in Psoriasis Patients of Color: Results of an Educational Intervention. (2022) (0)
Generalized morphea. (1998) (0)
Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis (2021) (0)
A Reduction in Dosage of Acitretin to 17.5 mg/day Maintains Efficacy While Improving Tolerability (2014) (0)
Combination of Calcipotriene Foam, 0.005% and Tazarotene Foam, 0.1% in the Treatment of Plaque Psoriasis of the Scalp and Body: A Case Report (2018) (0)
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica. (2023) (0)
Topical Immune Response Modifiers: Adjuvants (2008) (0)
25933 Tirbanibulin ointment 1% for actinic keratosis (AK): Pooled data from two phase 3 studies (2021) (0)
052 Vitiligo is characterized by multi-axis T-cell activation in blood (2018) (0)
Crisaborole Ointment Effect on Global Atopic Dermatitis Severity and Early Relief in Pruritus: Pooled Results From Two Phase 3 Clinical Trials (2018) (0)
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis (GPP) Flares. (2023) (0)
Risk of Rebound Psoriasis Flare from Systemic Corticosteroid Use in Patients with Psoriasis: A Retrospective Cohort Study. (2022) (0)
Vascular Effects of Pseudoxanthoma Elasticum (2021) (0)
Brodalumab: 4-Year US Pharmacovigilance Report. (2023) (0)
312 Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data From a Phase 2 Study (2021) (0)
301 Psoriatic arthritis risk in psoriasis patients in the Corrona® Psoriasis Registry (2021) (0)
Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting (2022) (0)
27629 Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population (2021) (0)
Case 2-1995. From the weekly grand rounds of the Department of Dermatology at the Mount Sinai Hospital. (1995) (0)
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD (2021) (0)
Crisaborole Topical Ointment, 2%, a novel nonsteroidal, anti-inflammatory, topical, phosphodiesterase 4 inhibitor, reduced pruritus and signs of atopic dermatitis in 2 phase 3 studies in children and adults with mild-to-moderate atopic dermatitis (2016) (0)
Pseudoxanthoma elasticum: Confirmation of linkage to 16p13.1 and demonstration of a largely recessive inheritance in unrelated families from the United Kingdom and North America (1998) (0)
26590 Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis with an acute flare (2021) (0)
Long-term safety of crisaborole ointment, 2%, across racial and ethnic groups (2018) (0)
Regular sunscreen use reduces invasive but not overall melanoma in white adults (2011) (0)
A study of the drug tildrakizumab in psoriasis patients (2020) (0)
Management of Pustular Psoriasis (1999) (0)
33467 Long-term safety and efficacy of roflumilast cream 0.3% in patients with chronic plaque psoriasis: Interim results from a 24-week, phase 3 open-label study (2022) (0)
P74: A review of pregnancy discussions and outcomes in the biologics for psoriasis cohort at our local trust (2022) (0)
33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry (2022) (0)
Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials (2019) (0)
Calcipotriene and Betamethasone Dipropionate: A Therapeutic Combination for Psoriasis (2006) (0)
Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)"" (2020) (0)
15914 Effect of metabolic syndrome on efficacy and safety in patients with psoriasis treated with etanercept or tildrakizumab: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2) (2020) (0)
Secukinumab in Psoriasis Patients With Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry (2017) (0)
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial (2022) (0)
15920 Relationship of serum glucose to efficacy and safety of tildrakizumab treatment for psoriasis in patients with and without metabolic syndrome from reSURFACE 1 and reSURFACE 2 (2020) (0)
Pregnancy and reproductive outcomes in pseudoxanthoma elasticum (1998) (0)
P-020 Clinical Outcomes Associated with Non-medical Switching or Discontinuation of Anti-TNF Inhibitors Among Patients with Inflammatory Bowel Disease (2016) (0)
Safe use of Interleukin-17 Inhibitors for Psoriasis and Psoriatic Arthritis in Two Patients with a History of Lymphoproliferative Disease (2020) (0)
Optimizing Therapy for Patients With Psoriasis (2015) (0)
Biologic Therapy for Systemic Sclerosis: A Systematic Review (2012) (0)
Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study (2020) (0)
Response to comment on "Risk of Rebound Psoriasis Flare from Systemic Corticosteroid Use in Patients with Psoriasis: A Retrospective Cohort Study". (2023) (0)
Are There Topical Corticosteroids with Improved Benefit-to-Risk Ratio? (1996) (0)
A Guide to Systemic Psoriasis Treatments: Methotrexate (2000) (0)
16830 Results from the open-label treatment period of a long-term proactive management phase III trial using fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam (2020) (0)
Genital Psoriasis: Safe, Effective Treatments Are Available (1997) (0)
189 Psoriasis age of onset: Effect on treatment outcomes in the PSOLAR registry (2017) (0)
ORIGINAL RESEARCH Impact of Temperature on Injection-Related Pain Caused by Subcutaneous Administration of Ustekinumab: A Three-Arm Open-Label Randomized Controlled Trial (2017) (0)
Iconography : Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study (2011) (0)
33993 Oral difelikefalin improves itch and quality of life in subjects with itch-dominant atopic dermatitis: Subgroup analysis of a randomized, phase 2 study (2022) (0)
Etanercept: A New Drug for the Treatment of Psoriatic Arthritis (2002) (0)
Rapid and sustained improvements in GPPGA scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. (2023) (0)
Secukinumab treatment provides fast relief from patient-reported psoriasis burden: (2015) (0)
No Increased Risk of Cancer after Coal Tar Treatment in Patients with Psoriasis or Eczema (2011) (0)
Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)" (2019) (0)
AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR (2021) (0)
Psoriasis Literature Review (1997) (0)
33968 Time to improvement in daily signs and symptoms associated with atopic dermatitis (AD) in patients with moderate-to-severe AD in pooled monotherapy studies of abrocitinib (2022) (0)
Supplemental material for "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)" (2020) (0)
AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2 (2021) (0)
SAT0560 Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Current Status of Observations (2015) (0)
Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial (2021) (0)
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004 (2010) (0)
In regards to Girard et a.l Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients. (2018) (0)
Nab-paclitaxel/Gemcitabine Induced Acquired Ichthyosis (2018) (0)
Be Prepared with Intervention for Methotrexate Overdose (1996) (0)
Case Profile: Female, 58, with 70% Body Coverage (1998) (0)
Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial (2020) (0)
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials (2022) (0)
Efficacy and safety of ABT-874, a monoclonal anti–interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial (2012) (0)
New Developments and Controversies in the Use of Methotrexate (1995) (0)
Psoriasis and Atopic Dermatitis: Addressing Therapeutic Paradigms by Learning from Each Other (2019) (0)
25602 Improvements and response achievement in PASI subscale domains for head scaling and erythema in apremilast-treated patients with moderate to severe plaque psoriasis of the scalp: Results from the STYLE study (2021) (0)
Scar classification in cutaneous lupus erythematosus: morphological description (2011) (0)
Combination Therapy: Retinoids and Ultraviolet Light (1999) (0)
Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials. (2023) (0)
Miscellaneous Uses of Biologic and Systemic Agents in Other Dermatologic Conditions (2018) (0)
15261 Lack of tuberculosis reactivation in 12,319 patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab: An ad hoc analysis of pooled safety data from 28 clinical trials (2020) (0)
Pulmonary Manifestations in Pseudoxanthoma Elasticum: A Review of Current Literature (2021) (0)
TNF-Alpha Class of Biologic Agents in Psoriatic Disease (2022) (0)
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis (2021) (0)
Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab (2012) (0)
Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2) (2022) (0)
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials (2022) (0)
The Efficacy of Certolizumab Pegol Re-Treatment on Plaque Psoriasis Following a Blinded Treatment Break: Results from the CIMPACT Trial (2019) (0)
Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol (2022) (0)
33270 Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up (2022) (0)
Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program (2023) (0)
Oral Difelikefalin Reduces Atopic Dermatitis–Associated Pruritus (2022) (0)
Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor (2018) (0)
Brodalumab Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe Psoriasis (2023) (0)
Using Genomics to Improve Pigmented Lesion Management & Health Outcomes (2022) (0)
Herpes Zoster Post-COVID-19 Vaccination in Young Adults (Under 35) (2022) (0)
Psoriasis in pregnancy: A review (2020) (0)
CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo (2022) (0)
Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial (2023) (0)
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials (2022) (0)
Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies (2022) (0)
New horizons in the management of psoriasis: introduction. (1998) (0)
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials (2022) (0)
Diagnostic Approach to Patients with Chronic Pruritus of Unknown Origin: A Single-Site Retrospective Chart Review (2022) (0)
Ustekinumab in the Treatment of Erythema Nodosum with Underlying Crohn’s Disease: A Case Report (2022) (0)
An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis (2022) (0)
Therapy for Head Lice: In Reply (2007) (0)
A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT) (2022) (0)
Two phase 3 study results of children and adults with mild-to-moderate atopic dermatitis treated with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor (2016) (0)
Evaluating Psoriasis in Patients (2008) (0)
Clinical Manifestations and Management Considerations of Psoriasis Affecting The Nail Unit (2018) (0)
Effects of Ultraviolet B Exposure on the Expression of Proliferating Cell Nuclear Antigen in Murine Skin ¶ (2004) (0)
A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults (2018) (0)
Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study (2020) (0)
15938 Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study (2020) (0)
27468 Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials (2021) (0)
Iconography : Compatibility of calcipotriene with other topical medications (2011) (0)
Nail Psoriasis: Management Presents Special Challenges (1996) (0)
Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study (2021) (0)
25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry (2021) (0)
27535 Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 104-week data from a phase 2 study (2021) (0)
Comprar Treatment of Skin Disease, 4th Edition | Warren R. Heymann | 9780702052354 | Saunders (2013) (0)
605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion (2020) (0)
Onset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies. (2022) (0)
Nerve Growth Factor Receptors on Dissociated Neurofibroma Schwann-like Cells12 (2006) (0)
World Psoriasis Conference 2006 (2005) (0)
Chapter 15 – Combination Therapies for Psoriasis (2016) (0)
Psoriasis medications: The future (2021) (0)
The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab (2012) (0)
Psychiatric implications of psoriasis. Authors' reply (2006) (0)
Pseudoxanthsoma elasticum: A sib pair and haplotype analysis at 16p reveals a largely dominant disorder with variable penetrance in unrelated families from the United Kingdom and North America (1998) (0)
Ixekizumab Overdose: A Case Report (2020) (0)
Overuse of black box warnings is scare tactic (2005) (0)
25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials (2021) (0)
27636 Addition of narrow-band ultraviolet light B phototherapy to ruxolitinib cream in patients with vitiligo (2021) (0)
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials (2023) (0)
25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study (2021) (0)
Vaccination of Patients on Biologic Agents for Psoriasis (2005) (0)
Musculoskeletal Symptoms with Long-term Acitretin Therapy for Psoriasis: An Age- and Sex-matched Retrospective Study (2008) (0)
Clinical Review a Practical Approach to the Use of Etanercept (2009) (0)
25572 Impact of risankizumab on the duration of PASI90 achievement: A post hoc analysis of 4 phase III clinical trials (2021) (0)
A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients (2010) (0)
Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitis (2004) (0)
Severe, Atypical Psoriatic Erythroderma and Hepatitis (1999) (0)
Sa544 THE BURDEN OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN CROHN'S DISEASE, ULCERATIVE COLITIS, PSORIASIS AND PSORIATIC ARTHRITIS (2021) (0)
25529 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: Updated pooled safety analyses (2021) (0)
Response to "Magnesium supplementation in the treatment of Pseudoxanthoma Elasticum: Is magnesium-oxide the best choice?" (2019) (0)
Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand (2021) (0)
Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab (2010) (0)
Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials (2021) (0)
Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation (2011) (0)
Altered steady state levels of mRNAs encoding isoforms of tropoelastin are associated with actinic elastosis (1998) (0)
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (2022) (0)
Dermatologic manifestations of systemic disease. (1998) (0)
059 Ixekizumab shows no association with MACE in patients with moderate-to-severe psoriasis: an integrated safety analysis of clinical trials (2016) (0)
Patient Satisfaction Scores and Standard of Care Compliance in Patients on Biologic Therapy for Psoriasis (2017) (0)
Expert Panel Discussion among Psoriasis and Psychodermatology Specialists: How Best to Manage Depressed Psoriasis Patients with Brodalumab (2019) (0)
Nerve Growth Factor Receptors on Dissociated Neurofibroma Schwann-like Cells 12 (2006) (0)
Improving Access to Care for Patients with Psoriasis and Psoriatic Arthritis: The Impact of the Temporary Reciprocity to Ensure Access to Treatment Act and Remote Care Policy Reform (2021) (0)
27568 Maintenance of repigmentation after discontinuation of ruxolitinib cream in patients with vitiligo (2021) (0)
Topical therapy I: corticosteroids and vitamin D analogs (2008) (0)
Appropriate use of alefacept therapy for psoriasis. Author's reply (2004) (0)
25754 Presence of psoriatic arthritis has no impact on the clinical efficacy and safety of secukinumab in patients with psoriasis: Pooled analysis of the phase 3 CLEAR and CLARITY trials (2021) (0)
13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis (2020) (0)
Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis (2023) (0)
Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion (2019) (0)
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry (2022) (0)
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. (2023) (0)
Secukinumab in Psoriasis Patients With Concurrent Psoriatic Arthritis: Demographics and Disease Characteristics in the Corrona Psoriasis Registry (2017) (0)
Retinoids: Ideal Adjunctive Psoriasis Therapy in Patients Prone to Skin Cancer (2006) (0)
26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry (2021) (0)
Handbook of Psoriasis (1999) (0)
Psoriasis with End Stage Renal Disease Successfully Treated with Ustekinumab: A Case Report (2020) (0)
PSS29 USTEKINUMAB IMPROVES DISEASE SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS WITH THE DERMATOLOGY LIFE QUALITY INDEX (2008) (0)
15277 Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials (2020) (0)
Free Communications 1 : Debate and Comments with the Expert Chairs CO 01 TOPICAL CORTICOSTEROID PHOBIA IN ATOPIC DERMATITIS : AN INTERNATIONAL VALIDATIONSTUDYOF THE TOPICOP SCORE (2016) (0)
Genital Lentigines in a 6-Year-Old Boy with a Family History of Cowden's Disease: Clinical and Genetic Evidence of the Linkage between Bannayan–Riley–Ruvacalba Syndrome and Cowden's Disease (2001) (0)
POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR (2021) (0)
Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study) (2023) (0)
Potential Use of TNF Inhibitors in the Treatment of Psoriasis 3 The Potential of TNF Inhibitors Relative to Other Therapies (2001) (0)
The Skin and Systemic Disease: A Color Atlas and Text (2003) (0)
Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints (2021) (0)
THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials (2016) (0)
Therapy of Mild-to-Moderate Psoriasis—Introduction (2006) (0)
Comprar Treatment of Skin Disease, 4th Edition | Mark G. Lebwohl | 9780702052354 | Saunders (2013) (0)
33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area (2022) (0)
Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis (2021) (0)
Use of TNF Inhibitors: The Changing Treatment Paradigm (2003) (0)
Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) (2020) (0)
Current Management of Generalized Pustular Psoriasis. (2023) (0)
Efﬁcacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study (2021) (0)
Patients With Psoriasis Treated With Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals With Potential Indicators of Early Nonalcoholic Fatty Liver Disease (2019) (0)
Acitretin for the Treatment of Psoriasis: A Case Report of Long-Lasting Alopecia (2015) (0)
P75: Exploratory quality of life and treatment satisfaction in two phase III studies of ruxolitinib cream in vitiligo (2022) (0)
15950 Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 2 study (2020) (0)
The 10 Most Common Mistakes in the Topical Treatment of Psoriasis (1997) (0)
14248 Efficacy and safety trends with continuous long-term use of 2% crisaborole ointment in patients with mild to moderate atopic dermatitis (2020) (0)
32805 Analysis of time to second relapse confirms the superiority of long-term proactive management with Cal/BD foam vs reactive management of psoriasis (2022) (0)
New Treatments Significantly Improve Responses in Patients With Plaque Psoriasis (2015) (0)
Case 1-1994. From the Weekly Grand Rounds of the Department of Dermatology at the Mount Sinai Hospital. (1995) (0)
Recurrent Keratoacanthoma (2020) (0)
291 Improvements in GPPGA score in patients experiencing a generalized pustular psoriasis (GPP) flare: Effisayil 1 study results (2022) (0)
17752 Effects of ruxolitinib cream on affected body areas in patients with vitiligo: Subgroup analysis from a 52-week, randomized, double-blind trial (2020) (0)
2018 Reviewer Thank You (2019) (0)
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials (2022) (0)
Mild to Moderate Psoriasis to Severe Psoriasis (2014) (0)
16865 Improvements in total dermatology life quality index by categories of skin clearance in clinical trials of brodalumab (2020) (0)
12797 Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial (2020) (0)
27476 Increased benefit of secukinumab vs ustekinumab in patients with psoriasis regardless of previous systemic psoriasis therapy: Pooled analysis of the phase 3 CLEAR and CLARITY trials (2021) (0)
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI) (2023) (0)
Reply to James Ferguson (2002) (0)
Chapter 16 – Investigational Therapies for Psoriasis (2016) (0)
N12. Psoriasis (1997) (0)
Emerging Research on Ingenol Mebutate Gel for Actinic Keratosis Treatment (0)
Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics. (2022) (0)
28043 Roflumilast cream significantly improves chronic plaque psoriasis in patients with steroid-sensitive area involvement (2021) (0)
Future psoriasis therapy : Psoriasis (1995) (0)
A 12-week open-label followed by 4-week double-blind study to determine the safety and efficacy of an extended course of alefacept (LFA-3/igg1 fusion protein) in subjects with chronic plaque psoriasis 1 1 Disclosure not available at press time. (2004) (0)
Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure. (2023) (0)
25985 Efficacy of tildrakizumab 100 mg for PASI improvement in patients with moderate to severe plaque psoriasis: Pooled analysis using nonresponder imputation from reSURFACE 1 and 2 through week 52 (2021) (0)
Online Education Yields Significant Gains in Physicians' Knowledge of Diagnosis and Management of Chronic Spontaneous Urticaria (2022) (0)
Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials (2021) (0)

This paper list is powered by the following services:

Other Resources About Mark G. Lebwohl

en.wikipedia.org

What Schools Are Affiliated With Mark G. Lebwohl?

Mark G. Lebwohl is affiliated with the following schools: